Mr. Cline received his undergraduate degree from San Diego State University and his MBA from Pepperdine University. We are monitoring the COVID-19 situation and have taken steps to ensure that access and … [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![])+(+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(+!![]))/+((!+[]+(!![])-[]+[])+(!+[]+(!![])-[])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])+!![]+!![])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(+!![])+(+!! Mr. Cline was instrumental in driving Adcetris’ continued revenue growth to over $475 million in 2018. This website is intended for a global audience. Prior to joining GW, Doug led the legal and compliance teams as Senior Vice President, General Counsel, and Secretary for Actelion US. GW Pharmaceuticals has 496 employees across 3 locations and £19.39 M in annual revenue in FY 2018. Suggested Broker Contact for conversion of Ordinary Shares to ADRs. GW PHARMACEUTICALS PLC - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity At GW Pharmaceuticals, our main concern is the well-being of our patients, healthcare partners, and employees. Our hearts and thoughts go out to the people who have been affected. Mr. Gover serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). During his tenure at GSK, Doug managed the legal and communications strategies related to some of the company’s most high profile matters concerning the New York Attorney General, the U.S. department of Justice and the FDA. Mr. Cline also held commercial leadership positions at Intermune and Amgen. See insights on GW Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Tina joined GW after a 14-year tenure at GlaxoSmithKline (GSK), where she most recently served as VP HR for GSK Europe and Global Therapeutic Groups. Prior to that, Doug held the position of Senior Vice President, General Counsel, Secretary at Eisai Inc. where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group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hile at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. GW Pharmaceuticals plc. as well as a doctorate degree in research on glioblastoma from the University at Cologne in Germany. Previous experience and roles at UCB included Managing Director Greece and Cyprus, and leader of all UCB activities on the orphan narcotic medication Xyrem, used in the treatment of narcolepsy.